TELA BioTELA +0.19%52 Days Payable is 43.28 as of Mar. 2026, which is 18% below its 10-year median of 52.54. GuruFocus rates TELA with a GF Score™ of 52/100 and a GF Value™ of $1.66 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 795 Medical Devices & Instruments companies, TELA Bio ranks worse than 76.48% on this metric.
TELA Bio's average Accounts Payable for the
three
months ended in Mar. 2026 was $3.10 Mil. TELA Bio's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $6.54 Mil.
Hence, TELA Bio's Days Payable for the
three
months ended in Mar. 2026 was 43.28.
The historical rank and industry rank for TELA Bio's Days Payable or its related term are showing as below:
TELA'
s Days Payable Range Over the Past 10 Years
Min: 30.51 Med: 52.54 Max: 321.11
Current: 39.5
During the past 9 years, TELA Bio's highest Days Payable was 321.11. The lowest was 30.51. And the median was 52.54.
TELA's Days Payable is ranked worse than 76.48% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs TELA: 39.50
TELA Bio's Days Payable
declined
from Mar. 2025 (46.70) to Mar. 2026 (43.28).
It may suggest that TELA Bioaccelerated paying its suppliers.
TELA Bio Days Payable Related Terms
TELA Bio Days Payable Historical Data
* Premium members only.
The historical data trend for TELA Bio's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, TELA Bio's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TELA Bio Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TELA Bio's Days Payable distribution charts can be found below:
* The bar in red indicates where TELA Bio's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
TELA Bio's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TELA Bio (TELA) has a Days Payable of 43.28 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on TELA Bio and its competitors. This is 18% below median its historical median of 52.54. Over the past decade, TELA Bio's Days Payable has ranged from 30.51 to 321.11. According to the industry distribution chart, TELA Bio ranks #608 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 76.5%.
Is TELA Bio's Days Payable too high?
TELA Bio's current Days Payable of 43.28 is 18% below median its 10-year median of 52.54. Over the past 10 years, this metric has ranged from a low of 30.51 to a high of 321.11. The Medical Devices & Instruments industry median Days Payable is 68.07. TELA Bio's value of 43.28 is 36.4% below this industry median. Based on the distribution chart, TELA Bio ranks #608 out of 795 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, TELA Bio has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TELA Bio's Days Payable compare to NSPR and BDMD?
According to the Medical Devices & Instruments industry distribution chart, TELA Bio ranks #608 out of 795 companies for Days Payable. This places TELA Bio in the lower half of its industry. The industry median Days Payable is 68.07. TELA Bio's value of 43.28 is 36.4% below this benchmark. Historically, TELA Bio's own Days Payable has ranged from 30.51 to 321.11 over the past decade. While the company's 10-year median is 52.54 vs. the industry median of 68.07, TELA Bio has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TELA Bio's current Days Payable of 43.28 is 36.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on TELA Bio and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TELA Bio's current Days Payable is 43.28, which is 18% below median its own 10-year median of 52.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TELA Bio stock overvalued right now?
Based on GuruFocus' analysis, TELA Bio (TELA) is currently considered Possible Value Trap. The stock's GF Value™ is $1.66, compared to a current price of $0.74 — trading 55.4% below its estimated fair value. The current Days Payable is 43.28, which is 18% below median its 10-year median of 52.54 and 36.4% below the Medical Devices & Instruments industry median of 68.07. TELA Bio's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For TELA Bio (TELA), the current Days Payable is 43.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TELA Bio (TELA) Overvalued in 2026?
Based on GuruFocus' analysis, TELA Bio stock appears to be undervalued.
The current stock price of $0.74 is trading 55.4% below its estimated GF Value™ of $1.66.
GuruFocus considers TELA Bio to be Possible Value Trap.
Key valuation signals for TELA:
Days Payable: 43.28 (18% below median its 10-year median of 52.54)
GF Value™: $1.66 vs. price of $0.74 (55.4% below fair value)
Industry Position: 36.4% below the Medical Devices & Instruments median (#608 of 795)
No single metric tells the full story. See the TELA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
52GF Score
Get the complete analysis for TELA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TELA has been successfully added to your 
